- Home
- GNPX vs HIHO Comparison
GNPX vs HIHO Comparison
Compare GNPX & HIHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- HIHO
- Stock Information
- Founded
- GNPX 2009
- HIHO 1990
- Country
- GNPX United States
- HIHO Hong Kong
- Employees
- GNPX N/A
- HIHO N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- HIHO Industrial Machinery/Components
- Sector
- GNPX Health Care
- HIHO Industrials
- Exchange
- GNPX Nasdaq
- HIHO Nasdaq
- Market Cap
- GNPX 7.0M
- HIHO 7.1M
- IPO Year
- GNPX 2018
- HIHO 1996
- Fundamental
- Price
- GNPX $0.25
- HIHO $1.94
- Analyst Decision
- GNPX Strong Buy
- HIHO
- Analyst Count
- GNPX 1
- HIHO 0
- Target Price
- GNPX $10.00
- HIHO N/A
- AVG Volume (30 Days)
- GNPX 2.9M
- HIHO 30.8K
- Earning Date
- GNPX 05-12-2025
- HIHO 01-21-2025
- Dividend Yield
- GNPX N/A
- HIHO 6.21%
- EPS Growth
- GNPX N/A
- HIHO N/A
- EPS
- GNPX N/A
- HIHO N/A
- Revenue
- GNPX N/A
- HIHO $7,345,000.00
- Revenue This Year
- GNPX N/A
- HIHO N/A
- Revenue Next Year
- GNPX N/A
- HIHO N/A
- P/E Ratio
- GNPX N/A
- HIHO N/A
- Revenue Growth
- GNPX N/A
- HIHO 11.36
- 52 Week Low
- GNPX $0.22
- HIHO $1.39
- 52 Week High
- GNPX $4.09
- HIHO $2.88
- Technical
- Relative Strength Index (RSI)
- GNPX 43.11
- HIHO 73.09
- Support Level
- GNPX $0.22
- HIHO $1.74
- Resistance Level
- GNPX $0.36
- HIHO $2.00
- Average True Range (ATR)
- GNPX 0.03
- HIHO 0.10
- MACD
- GNPX -0.00
- HIHO 0.04
- Stochastic Oscillator
- GNPX 22.05
- HIHO 85.71
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. The company is a manufacturer of metal, plastic, electric and electronic components for original equipment manufacturers (OEM) and contract manufacturers. Its operating segment includes Metal stamping and mechanical OEM and Electric OEM. The metal stamping segment focuses on the manufacturing and sale of metal parts and components. The company generates maximum revenue from the Metal stamping and mechanical OEM segment. Geographically, it derives a majority of its revenue from Europe and also has a presence in Hong Kong and China, North America, and Other Asian countries.